Manfredi Rizzo

Q: What Schools Are Affiliated With Manfredi Rizzo

Manfredi Rizzo is affiliated with the following schools: University of South Carolina, University of Milan, University of Oxford, Stanford University, University of Palermo, Carol Davila University of Medicine and Pharmacy

Manfredi Rizzo's AcademicInfluence.com Rankings

Manfredi Rizzo

Computer Science

#7656

World Rank

#8060

Historical Rank

Machine Learning

#2898

World Rank

#2934

Historical Rank

Artificial Intelligence

#3192

World Rank

#3239

Historical Rank

Database

#4708

World Rank

#4891

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Manfredi Rizzo's Degrees

PhD Computer Science University of Milan
Masters Artificial Intelligence University of Oxford
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Manfredi Rizzo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Manfredi Rizzo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. (2006) (390)
Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. (2011) (309)
Complications of Diabetes 2017 (2018) (305)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (2015) (299)
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel (2017) (289)
Low-density lipoprotein size and cardiovascular risk assessment. (2006) (258)
Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation (2017) (251)
An update on the role of markers of inflammation in atherosclerosis. (2010) (199)
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. (2011) (196)
The Role of Nutraceuticals in Statin Intolerant Patients. (2018) (191)
Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. (2015) (170)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel (2015) (167)
Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. (2015) (163)
Clinical review: Association between metabolic syndrome and periodontitis: a systematic review and meta-analysis. (2013) (162)
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel# (2017) (151)
Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. (2015) (135)
Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. (2009) (132)
Management of Statin Intolerance in 2018: Still More Questions Than Answers (2018) (131)
Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches (2013) (126)
A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations (2015) (125)
Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. (2015) (121)
Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial (2016) (118)
Nationwide and Long-Term Survey of Primary Glomerulonephritis in Japan as Observed in 1,850 Biopsied Cases (1999) (117)
Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. (2006) (117)
Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. (2007) (116)
Atherogenic dyslipidemia and oxidative stress: a new look. (2009) (116)
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. (2011) (116)
Prevalence of dyslipidemia and associated risk factors in Turkish adults. (2014) (112)
Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study (2016) (102)
The role of fibrate treatment in dyslipidemia: an overview. (2013) (100)
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. (2013) (94)
Small, dense low‐density lipoproteins (LDL) are predictors of cardio‐ and cerebro‐vascular events in subjects with the metabolic syndrome (2009) (94)
Natural approaches in metabolic syndrome management (2017) (94)
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study (2016) (93)
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. (2018) (92)
COVID-19 and diabetes management: What should be considered? (2020) (90)
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. (2015) (88)
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors (2009) (86)
Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. (2020) (86)
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study (2014) (85)
Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. (2009) (83)
Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome (2009) (83)
Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases. (2018) (82)
Ethnic differences in serum lipoproteins and their determinants in South African women. (2010) (80)
Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month follow-up study (2008) (79)
Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. (2014) (79)
Small, dense low‐density‐lipoproteins and the metabolic syndrome (2007) (77)
Safety of red yeast rice supplementation: A systematic review and meta‐analysis of randomized controlled trials (2019) (77)
Should we measure routinely the LDL peak particle size? (2006) (76)
Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes (2008) (74)
Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. (2009) (73)
Who needs to care about small, dense low‐density lipoproteins? (2007) (72)
The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins (2006) (72)
Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. (2008) (72)
Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. (2010) (70)
Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? (2005) (70)
An update on the relationships between rheumatoid arthritis and atherosclerosis. (2010) (68)
Should low high-density lipoprotein cholesterol (HDL-C) be treated? (2014) (67)
Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. (2014) (66)
Hsp60 and heme oxygenase-1 (Hsp32) in acute myocardial infarction. (2011) (64)
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? (2013) (63)
Long-term consequences of polycystic ovary syndrome on cardiovascular risk. (2009) (61)
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis (2014) (56)
Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. (2016) (56)
Intensive LDL‐cholesterol lowering therapy and neurocognitive function (2017) (54)
PCSK9 inhibition - a novel mechanism to treat lipid disorders? (2013) (53)
Predictors of Insulin Resistance in Patients With Obesity (2014) (51)
Markers of inflammation are strong predictors of subclinical and clinical atherosclerosis in women with hypertension (2009) (50)
The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). (2020) (50)
NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet (2017) (50)
Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. (2015) (50)
Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study (2012) (49)
Death by SARS-CoV 2: a Romanian COVID-19 multi-centre comorbidity study (2020) (49)
The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease (2015) (47)
The significance of low-density-lipoproteins size in vascular diseases. (2006) (47)
Evaluation of serum sIgE / total IgE ratio in predicting clinical response to allergen-specific immunotherapy (2009) (46)
Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress (2016) (45)
Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol. (2008) (45)
LDL size: does it matter? (2004) (45)
The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. (2007) (42)
Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. (2006) (41)
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials (2013) (40)
Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? (2013) (40)
Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review (2008) (40)
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. (2008) (39)
ETC-1002: a future option for lipid disorders? (2014) (39)
Effects of Mediterranean Diet on Lipid Levels and Cardiovascular Risk in Renal Transplant Recipients (1999) (38)
Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. (2005) (37)
Low-density lipoprotein size and cardiovascular prevention. (2006) (37)
Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns? (2016) (37)
Heat shock protein-60 and risk for cardiovascular disease. (2011) (37)
The effect of bergamot on dyslipidemia. (2016) (36)
Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study (2018) (36)
Changes in Immunohistochemical Levels and Subcellular Localization After Therapy and Correlation and Colocalization With CD68 Suggest a Pathogenetic Role of Hsp60 in Ulcerative Colitis (2011) (36)
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study (2015) (36)
Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits (2003) (35)
Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials (2017) (35)
New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension (2014) (35)
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? (2021) (35)
How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? (2008) (35)
Effects of Chitosan on Plasma Lipids and Lipoproteins (2014) (35)
Statins and new-onset diabetes. (2014) (35)
Should we routinely measure low-density and high-density lipoprotein subclasses? (2009) (34)
Gut microbiota and aging-A focus on centenarians. (2020) (34)
Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. (2017) (34)
Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials (2019) (34)
Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes (2008) (33)
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? (2011) (33)
Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm (2017) (33)
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates (2007) (32)
Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. (2017) (32)
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect (2020) (32)
Fever of unknown origin in a Mediterranean survey from a division of internal medicine: report of 91 cases during a 12-year-period (1991–2002) (2008) (31)
Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel (2021) (31)
Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. (2005) (31)
LDL size and subclasses in patients with abdominal aortic aneurysm. (2009) (31)
Anti-cytokine therapy for prevention of atherosclerosis. (2016) (31)
Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review (2020) (31)
Gender differences in the battle against COVID‐19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes (2020) (31)
New lipid modulating drugs: the role of microsomal transport protein inhibitors. (2011) (31)
Serum low density lipoprotein subclasses in asthma. (2013) (30)
Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study (2019) (30)
Effects of Coenzyme Q 10 on Statin-Induced Myopathy : A Meta-analysis of Randomized Controlled Trials (2014) (30)
The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? (2009) (29)
Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. (2015) (29)
The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? (2009) (29)
Nutritional Characteristics of a Rural Southern Italy Population: The Ventimiglia di Sicilia Project (2002) (29)
Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome (2015) (29)
Long-Term Brain Disorders in Post Covid-19 Neurological Syndrome (PCNS) Patient (2021) (29)
Periodontitis and mechanisms of cardiometabolic risk: Novel insights and future perspectives. (2019) (29)
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. (2020) (29)
An overview of statin-induced myopathy and perspectives for the future (2020) (28)
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up (2013) (28)
Post-Acute COVID-19 Neurological Syndrome: A New Medical Challenge (2021) (28)
The metabolic syndrome and HIV infection. (2014) (28)
An evaluation of RVX-208 for the treatment of atherosclerosis (2015) (28)
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights (2020) (27)
The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? (2008) (27)
Nutraceuticals in Lipid-Lowering Treatment (2015) (27)
Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level (2014) (27)
Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. (2010) (27)
Incretin-based therapies, glucometabolic health and endovascular inflammation. (2014) (26)
Small, dense LDL: an update (2017) (26)
Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers. (2014) (26)
Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. (2003) (26)
Should we measure routinely oxidised and atherogenic dense low‐density lipoproteins in subjects with type 2 diabetes? (2010) (26)
ApoE polymorphism in a small Mediterranean island: Relationships with plasma lipids, lipoproteins and LDL particle size (2004) (25)
Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. (2007) (24)
Prediction of Cerebrovascular and Cardiovascular Events in Patients With Subclinical Carotid Atherosclerosis (2008) (24)
The predictive role of C‐reactive protein in patients with hypertension and subclinical atherosclerosis (2009) (24)
High-Resolution Computed Tomography Quantitation of Emphysema Is Correlated with Selected Lung Function Values in Stable COPD (2011) (24)
There is more to predicting vascular disease than just established risk factors. (2011) (24)
New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! (2015) (24)
Future perspectives of the pharmacological management of diabetic dyslipidemia (2019) (23)
Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study. (2005) (23)
Oxidative stress markers at birth: Analyses of a neonatal population. (2015) (23)
Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies (2020) (23)
Lipid-lowering therapies and achievement of LDL-cholesterol targets (2012) (22)
Short-Term Impact of a Combined Nutraceutical on Cognitive Function, Perceived Stress and Depression in Young Elderly with Cognitive Impairment: A Pilot, Double-Blind, Randomized Clinical Trial. (2017) (22)
High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: a 20-year prospective study (2014) (22)
Short-Term Effects of a Combined Nutraceutical on Lipid Level, Fatty Liver Biomarkers, Hemodynamic Parameters, and Estimated Cardiovascular Disease Risk: A Double-Blind, Placebo-Controlled Randomized Clinical Trial (2017) (22)
Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study (2020) (22)
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. (2019) (22)
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia (2021) (21)
Uric acid metabolism in pre-hypertension and the metabolic syndrome. (2014) (21)
A review of the cardiovascular and anti-atherogenic effects of ghrelin. (2013) (21)
Effects of obesity and estradiol on Na+/K+-ATPase and their relevance to cardiovascular diseases. (2013) (20)
The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis (2017) (20)
Statins, Fracture Risk, and Bone Remodeling: What Is True? (2006) (20)
Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL (2022) (20)
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) (2022) (20)
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP) (2022) (20)
Hydroxychloroquine, COVID‐19 and diabetes. Why it is a different story (2020) (20)
Plasma heme oxygenase-1 is decreased in peripheral artery disease patients. (2016) (20)
Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. (2006) (20)
Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients (2007) (20)
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia (2011) (20)
Oral manifestations of inflammatory bowel disease. (2017) (19)
Comparison of Reported Deaths From COVID-19 and Increase in Total Mortality in Italy. (2020) (19)
Rational for statin use in psoriatic patients (2013) (19)
Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions (2008) (19)
Rickettsial disease: classical and modern aspects. (2004) (19)
The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective (2013) (19)
Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. (2004) (19)
Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options (2021) (18)
LDL and HDL subfractions, dysfunctional HDL: treatment options. (2014) (18)
Gut Microbiota, Obesity and Bariatric Surgery: Current Knowledge and Future Perspectives. (2019) (18)
Size and Subclasses of Low-Density Lipoproteins in Patients With Obstructive Sleep Apnea (2012) (18)
Exploring the Role of Skeletal Muscle in Insulin Resistance: Lessons from Cultured Cells to Animal Models (2021) (18)
Changes in plasma lipids and low-density lipoprotein peak particle size during and after acute myocardial infarction. (2002) (17)
Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes (2010) (17)
Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. (2011) (17)
The Role of Fructose as a Cardiovascular Risk Factor: An Update (2022) (17)
Association between COX-2 rs 6681231 Genotype and Interleukin-6 in Periodontal Connective Tissue. A Pilot Study (2014) (17)
Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography (2007) (17)
Clinical Importance of Eosinophil Count in Nasal Fluid in Patients with Allergic and Non-Allergic Rhinitis (2009) (17)
IMPROVE-IT: what have we learned? (2016) (17)
Novel Therapeutical Approaches to Managing Atherosclerotic Risk (2021) (16)
The Role of Endothelium in COVID-19 (2021) (16)
Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome. (2011) (16)
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review (2022) (16)
The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis. (2009) (16)
Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis (2018) (16)
Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. (2006) (15)
Recent Insights Into the Relationship Between Inflammatory Liver Diseases and Atherosclerosis (2011) (15)
Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets (2021) (15)
Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2). (2011) (15)
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. (2014) (15)
Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies (2019) (15)
Clinical benefits of ezetimibe use: is absence of proof, proof of absence? (2012) (15)
Incretin-based therapies in 2021 – Current status and perspectives for the future (2021) (15)
"Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: The need for a call to action". (2020) (15)
The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel (2022) (14)
Preliminary Results of CitraVes™ Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study (2021) (14)
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial (2013) (14)
Lipid subclasses profiles and oxidative stress in aggressive periodontitis before and after treatment. (2015) (14)
Tea catechins induce crosstalk between signaling pathways and stabilize mast cells in ulcerative colitis. (2017) (14)
Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: physician survey and good clinical practice recommendations from an International Expert Panel. (2020) (14)
The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review (2017) (14)
NLRP3 Inflammasome Biomarker—Could Be the New Tool for Improved Cardiometabolic Syndrome Outcome (2020) (14)
PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk. (2017) (13)
Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study (2020) (13)
Androgen excess and cardiovascular risk. (2007) (13)
Physical Exercise and DNA Injury: Good or Evil? (2017) (13)
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review (2021) (13)
DIABETES AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM: IMPLICATIONS FOR COVID-19 PATIENTS WITH DIABETES TREATMENT MANAGEMENT (2020) (13)
Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study (2022) (12)
Metabolic disorders during pregnancy and postpartum cardiometabolic risk (2018) (12)
CORRELATIONS OF SERUM INTERLEUKIN-16 , TOTAL IgE , EOSINOPHIL CATIONIC PROTEIN AND TOTAL EOSINOPHIL COUNTS WITH DISEASE ACTIVITY IN CHILDREN WITH ATOPIC DERMATITIS (2011) (12)
Incretins, Pregnancy, and Gestational Diabetes. (2016) (12)
Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial (2014) (12)
Therapeutic patient education in oncology: pedagogical notions for women's health and prevention. (2007) (12)
Quantitative and qualitative effects of rosuvastatin on LDL‐cholesterol: what is the clinical significance? (2009) (12)
The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart (2021) (12)
A case of bowel schistosomiasis not adhering to endoscopic findings. (2005) (11)
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies (2022) (11)
Postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia (2021) (11)
Pharmacotherapy for gestational diabetes (2018) (11)
Gestational diabetes and the metabolic syndrome: can obesity and small, dense low density lipoproteins be key mediators of this association? (2014) (11)
Statins in liver disease: not only prevention of cardiovascular events (2018) (10)
Statin intolerance: new data and further options for treatment (2021) (10)
Statin treatment in the elderly: how much do we know? (2013) (10)
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism (2021) (10)
Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. (2021) (10)
Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: A one-year follow-up study. (2005) (10)
Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients (2015) (10)
Non-glycemic effects of pioglitazone and incretin-based therapies (2013) (10)
Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect (2020) (10)
The effects of statins on blood pressure: current knowledge and future perspectives (2012) (9)
Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies (2021) (9)
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. (2022) (9)
Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation. (2012) (9)
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction (2022) (9)
Statins and osteoporosis: myth or reality? (2004) (9)
Post-COVID syndrome, inflammation, and diabetes (2022) (9)
Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH. (2014) (8)
Interleukin‐18 levels are associated with low‐density lipoproteins size (2010) (8)
Is diabetes the cost to pay for a greater cardiovascular prevention? (2010) (8)
Vitamin D in the Prevention and Treatment of Diabetic Neuropathy. (2022) (8)
Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications (2021) (8)
Nonalcoholic Fatty Liver Disease, Cardiovascular Risk, and Carotid Inflammation (2015) (8)
Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome (2011) (8)
Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health (2022) (8)
Efficacy of a fasting-mimicking diet in functional therapy for depression: A randomised controlled pilot trial. (2020) (7)
Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues (2021) (7)
Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses. (2013) (7)
Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy (2007) (7)
CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities (2021) (7)
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study (2022) (7)
A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin (2019) (7)
Investigating dysfunctional-hdl in selected groups of patients at high risk of cardiovascular events (DYS-HDL study) - Protocol and organization (2014) (7)
Metabolic Syndrome and Vitamin D Levels in Patients with Obstructive Sleep Apnea Syndrome. (2018) (7)
Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives (2015) (7)
Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk 1 (2012) (7)
Metabolic Syndrome in Patients with Coexistent Obstructive Sleep Apnea Syndrome and Chronic Obstructive Pulmonary Disease (Overlap Syndrome). (2020) (7)
Novel anti-obesity drugs and plasma lipids (2014) (7)
Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers. (2019) (6)
Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. (2021) (6)
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022) (2022) (6)
The Role of Elevated Growth Hormone on the Increased Atherosclerosis in Patients With Acromegaly (2012) (6)
In vivo triglyceride synthesis in subcutaneous adipose tissue of humans correlates with plasma HDL parameters. (2016) (6)
Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome. (2016) (6)
Emerging approaches for the treatment of hypertriglyceridemia (2013) (6)
Distribution of risk factors, plasma lipids, lipoproteins and dyslipidemias in a small Mediterranean island: the Ustica Project. (2002) (6)
New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications? (2021) (6)
Metformin: Sex/Gender Differences in Its Uses and Effects—Narrative Review (2022) (6)
Prevalence of metabolic syndrome: a comparative analysis in an unselected sample of mediterranean subjects. (2012) (6)
Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care (2021) (6)
Genetic and Epigenetic Biomarkers For Diagnosis, Prognosis and Treatment Of Metabolic Syndrome. (2021) (6)
Managing the Systemic Impact of Periodontitis (2022) (5)
Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea (2016) (5)
Preliminary Results of CitraVesTM Effects on Low Density Lipoprotein Cholesterol and Waist Circumference in Healthy Subjects after 12 Weeks: A Pilot Open-Label Study (2021) (5)
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective (2021) (5)
Cardiovascular effects of glucagon‐like peptide‐1 receptor agonist therapies in patients with type 1 diabetes (2017) (5)
Diabetes and COVID-19: A Tale of 2 Pandemics (2021) (5)
PPAR in Cardiovascular Disorders (2016) (5)
Post-prandial alterations in LDL size and subclasses in patients with growth hormone deficiency. (2008) (4)
New antihyperglycaemic agents and cardiovascular disease: let's be optimistic (2018) (4)
Serum lipoproteins are not associated with the severity of asthma. (2018) (4)
SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL (2016) (4)
Weight loss programmes using low carbohydrate diets to control the cardiovascular risk in adolescents (Review). (2020) (4)
Therapy with noninvasive ventilation in patients with obstructive sleep apnoea: effects on atherogenic lipoprotein phenotype. (2009) (4)
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes (2022) (4)
Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care (2021) (4)
Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions (2022) (4)
The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact (2022) (4)
Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections (2022) (3)
Treatment options for managing atherogenic dyslipidemia and fatty liver disease (2014) (3)
Neuroendocrine tumors diagnosed at the Antonio Cardarelli hospital (Naples, Italy) between 2006-2009: a single-institution analysis. (2011) (3)
Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes (2021) (3)
The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis (2022) (3)
When Periods Stop: Long-Term Consequences of PCOS (2009) (3)
Safe and successful endoarterial infusion of liposomal amphotericin B in treatment of mucormycosis. (2003) (3)
A New Comorbidity in Periodontitis: Fusobacterium nucleatum and Colorectal Cancer (2022) (3)
Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents (2021) (3)
Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients. (2022) (3)
Effect of statins on low-density lipoprotein size: a new role in cardiovascular prevention? (2006) (3)
Glucose Metabolism Disorders: Challenges and Opportunities for Diagnosis and Treatment (2022) (3)
Microvascular and macrovascular effects of liraglutide. (2019) (3)
Effect of Bariatric Surgery on Intima Media Thickness: A Systematic Review and Meta-Analysis (2022) (3)
Neurological Consequences, Mental Health, Physical Care, and Appropriate Nutrition in Long-COVID-19 (2022) (3)
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes (2022) (3)
Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease (2021) (3)
Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review (2021) (3)
Role of Chemerin in Cardiovascular Diseases (2022) (3)
Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. (2021) (3)
Oxidative stress and small, dense low-density lipoproteins: current and future perspectives (2012) (3)
Metformin Modulates the Mechanisms of Ageing (2019) (3)
GLP-1 receptor agonists, carotid atherosclerosis and retinopathy (2017) (3)
Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS) (2022) (3)
Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion (2020) (2)
A Potential Link between Serum Low-Density Lipoproteins and Asthma. (2015) (2)
The Role of Advanced Glycation End Products on Dyslipidemia (2023) (2)
The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest (2022) (2)
Medical therapy for patients with subclinical and clinical carotid atherosclerosis. (2012) (2)
Editorial [Inflammation and Atherosclerosis: Recent Insights and Future Perspectives] (2008) (2)
Can statins mitigate the adverse cardiovascular effects of smoking? (2013) (2)
Effects “beyond-cholesterol” by statins: a 3-months therapy with simvastatin reduces the atherogenic lipoproteins in patients with premature coronary artery disease and in absence of the traditional cardiovascular risk factors. (2004) (2)
Metabolic Effect Of Berberine-Silymarin Association: A Meta-Analysis Of Randomized, Double-Blind, Placebo-Controlled Clinical Trials (2019) (2)
Recent insights on dark chocolate consumption and cardiovascular risk. (2008) (2)
The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials (2022) (2)
Safety and outcomes of intravitreal aflibercept in diabetic macular edema - a systematic review. (2022) (2)
Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path! (2022) (2)
Psoriasis and acute coronary syndrome risk. (2019) (2)
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence (2022) (2)
Statins and angiogenesis in non-cardiovascular diseases. (2022) (2)
Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome (2022) (2)
Infection and inflammation influence the outcome of patients with asymptomatic carotid lesions. Int Angiol. 2004. 23(suppl.1) (2004) (2)
The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis (2006) (2)
Can the effects of gender, menopause and ageing on lipid levels be differentiated? (2016) (2)
Advanced Glycation End Products: Do They Impair Bone Health in Diabetes? (2022) (2)
Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. (2004) (2)
Effects “beyond-cholesterol” by statins: a 3-months therapy with simvastatin reduces the atherogenic lipoproteins in patients with premature coronary artery disease and in absence of the traditional cardiovascular risk factors. (2004) (2)
ApoE genotype distribution in a low-cholesterol mediterranean population of Southern Italy (1997) (2)
An update on the role of the quality of LDL in cardiovascular risk: the contribution of the universities of Palermo and Zurich. (2007) (2)
Associations between cardiovascular disease, cancer and very low HDL cholesterol in the REasons for Geographical And Racial Differences in Stroke (REGARDS) study. (2017) (2)
Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas? (2018) (2)
Letter to editor A practical method to determine the “atherogenic lipoprotein phenotype” (2008) (2)
High-Sensitivity C-Reactive Protein and Statin Initiation (2015) (2)
The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. (2023) (1)
[Urticaria and angioedema. An internal disorder with cutaneous manifestation]. (2004) (1)
The Role of Macrophage Colony-Stimulating Factor in Patients With Acute Myocardial Infarction (2012) (1)
Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect? (2021) (1)
Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope? (2013) (1)
Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability. (2003) (1)
Microvascular Complications of Diabetes Mellitus: Focus on Diabetic Retinopathy (DR) and Diabetic Foot Ulcer (DFU) (2021) (1)
Molecular Endocrinology and Metabolism in 2021: What’s New (2021) (1)
INSIGHTS INTO CHRONONUTRITION: THE INNERMOST INTERPLAY AMONGST NUTRITION, METABOLISM AND THE CIRCADIAN CLOCK, IN THE CONTEXT OF EPIGENETIC REPROGRAMMING (2019) (1)
THE SIGNIFICANCE OF SPONTANEOUS AND INDUCED APOPTOSIS IN TERMS OF CELL PROLIFERATION REGULATION, WITH SPECIFIC REFERENCE TO THE INTESTINE (2018) (1)
Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention (2022) (1)
[Three cases of bartonellosis (cat scratch disease)]. (2002) (1)
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes (2011) (1)
Mipomersen: a lipid-lowering agent with a novel mechanism of action (2013) (1)
The regulation of efferocytosis signaling pathways and adipose tissue homeostasis in physiological conditions and obesity: Current understanding and treatment options (2022) (1)
Correction: A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin (2019) (1)
Treating Arterial Stiffness Associated with Features of Metabolic Syndrome Not Included in its Diagnostic Criteria: Cutting Off the Heads of Lernaean Hydra, Keeper of the Underworld (2013) (1)
P242 INCREASED PLASMA RESISTIN CONCENTRATIONS ARE ASSOCIATED WITH ATHEROGENIC SMALL, DENSE LOW-DENSITY LIPOPROTEINS IN PATIENTS WITH TYPE-2 DIABETES (2010) (1)
Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic Syndrome) (2014) (1)
Diabetes, family history and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one year follow-up study (2004) (1)
Update on the role of the atherogenic lipoprotein phenotype in cardiovascular prevention. (2007) (1)
Managing the Cardiovascular Risk Associated with the Metabolic Syndrome (2014) (1)
Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom? (2015) (1)
Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs – The CAPISCO International Expert Panel (2022) (1)
Beneficial effects of liraglutide on carotid intima-media thickness in patients with type 2 diabetes: a 8-month prospective study (2013) (1)
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective (2022) (1)
The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis (2022) (1)
Critical questions in diabetes management: What are the most compelling challenges and how can we handle them? (2022) (1)
[The extra-glycemic effects of liraglutide: focus on cardiometabolic markers]. (2016) (1)
Obesity and HFpEF (2022) (1)
The Endometrial Transcriptome of Metabolic and Inflammatory Pathways During the Window of Implantation Is Deranged in Infertile Obese Polycystic Ovarian Syndrome Women. (2022) (1)
Associations between Periodontitis, COVID-19, and Cardiometabolic Complications: Molecular Mechanisms and Clinical Evidence (2022) (1)
Accumulation of ApoE-containing triglyceride-rich lipoproteins in normolipidemic men with premature coronary artery disease (2000) (1)
Low- and High-Density Lipoprotein Subclasses in Subjects with Non-Alcoholic Fatty Liver Disease (2016) (1)
Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot (2022) (1)
Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia (2022) (1)
The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update (2022) (1)
Effects of Armolipid Plus® on small dense LDL particles (2016) (1)
The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease (2015) (1)
Kidney Manifestations of Inflammatory Bowel Diseases (2018) (1)
Author's response. (2013) (1)
Alcoholic liver cirrhosis, more than a simple hepatic disease – A brief review of the risk factors associated with alcohol abuse (2019) (1)
Nutraceuticals and Lipid Management (2020) (1)
Periodontitis, blood lipids and lipoproteins (2014) (1)
Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). (2023) (1)
Hypothyroidism and Risk of Cardiovascular Disease. (2022) (1)
Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice (2021) (1)
Cognitive benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu. (2023) (1)
Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children (2018) (1)
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date (2022) (1)
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update (2023) (1)
Neuroendocrine Tumors Diagnosed at the “Antonio Cardarelli” Hospital (Naples, Campania, Italy) between 2006–2009: A Single-Institution Analysis (2011) (1)
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis (2022) (1)
Clinical predictors of adverse events in a 1 year follow-up study post-PTCA. (2002) (0)
3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis (2017) (0)
Effects of Dark Chocolate on Cardiovascular Risk (2010) (0)
Effects of Trehalose Administration in Patients with Mucopolysaccharidosis Type III. (2023) (0)
Timing Is Important—Management of Metabolic Syndrome According to the Circadian Rhythm (2023) (0)
Weight response to GLP-1 receptor agonists: Why women do it better? (2022) (0)
Does the Hyperglycemia Impact on COVID-19 Outcomes Depend upon the Presence of Diabetes?—An Observational Study (2022) (0)
Evaluation of serum-specific IgE/total IgE ratio in predicting clinical response to allergen specific immunotherapy. (2009) (0)
CD14 C(-260)>T gene polymorphism is not a risk factor for myocardial infarction (2002) (0)
Upstream comprehensive management of individuals with diabetes with multimorbidity and frailty to act against amputation. (2023) (0)
64 THE ATHEROGENIC LIPOPROTEIN PHENOTYPE AND LDL SIZE AND SUBCLASSES IN WOMEN WITH GESTATIONAL DIABETES (2008) (0)
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis (2023) (0)
Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem! (2014) (0)
Increased plasma resistin concentrations are associated with atherogenic small, dense low-density lipoproteins in patients with type-2 diabetes (2010) (0)
Metformin in SARS-CoV-2 infection: A hidden path – from altered inflammation to reduced mortality. A review from the literature (2023) (0)
Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly (2022) (0)
PP172 ASSOCIATIONS OF FRUCTOSE AND GLUCOSE CONSUMPTION WITH LDL PARTICLE SIZE IN THE DIET OF HEALTHY SWISS MEN (2010) (0)
Joint Annual Meeting of the, Swiss Society of Pneumology, Swiss Society of Pediatric Pneumology, Swiss Society for Thoracic Surgery, Swiss Underwater and Hyperbaric Medical Society, Crans-Montana, April 25–27, 2012 (2012) (0)
Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes (2023) (0)
Do We Need Better Lipid Tools for Cardiovascular Risk Assessment? Authors' reply (2008) (0)
Editorial: Diet-microbe-host interactions in metabolic syndrome (2023) (0)
Fasting and postprandial effects of rosiglitazone on low- and high-density lipoproteins size and subclasses in type-2 diabetes (2010) (0)
O46 Comparison between different mathematical methods to calcolate insulin resistance in women with polycystic ovary syndrome (PCOS) (2003) (0)
Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study (2014) (0)
W16-P-075 Effects of combined estrogen+progestin hormone therapy on hepatic lipase and lipoprotein lipase levels (2005) (0)
Clinical anatomic, immunomorphologic and molecular anatomic data suggest interplay of thyroidal molecules, autoantibodies and Hsp60 in Hashimoto’s disease (2013) (0)
Epicardial, peripancreatic and other "orthotopic" excessive fat deposition in south Asians and Europeans: Are differences clinically relevant? (2023) (0)
4.30 Impact of Diabetes and Impaired Glucose Tolerance (IGT) on Complications and Hospitalisation in Patients with Acute Coronary Syndrome (2007) (0)
Nutraceuticals and Cardiovascular Disease (2021) (0)
NUTRACEUTICALS IMPROVE EXPERIMENTAL COLITIS: PLACE OF CATECHINS IN THE 2,4,6-TRINITROBENZENE SULFONIC ACID MODEL RATS (2017) (0)
Non-classic forms of atherogenic dyslipidemia in women with polycystic ovary syndrome. (2008) (0)
COMPARATIVE EFFECTS OF ROSIGLITAZONE AND PIOGLITAZONE ON FASTING AND POSTPRANDIAL LDL-SIZE AND SUBCLASSES IN PATIENTS WITH TYPE-2 DIABETES (2008) (0)
We-P11:264 Use of stents with sirolimus is significantly associated with a reduction in mortality and cardiovascular morbidity at 6- and 12-months post-PTCA (2006) (0)
1443Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials (2019) (0)
The Na+/K+-ATPase: A potential therapeutic target in cardiometabolic diseases (2023) (0)
Rizzo et al-2010-IJCP OxidizedLDL (2015) (0)
PEAK PARTICLE SIZE AND THE EXTENSION OF CORONARY ATHEROSCLEROSIS IN 71 PATIENTS THAT UNDERWENT AN ANGIOGRAPHIC EXAM (2004) (0)
A cc ep te d A rti cl e Cardiovascular Effects of GLP-1 Receptor Agonist Therapies in Patients with Type-1 Diabetes (2017) (0)
Future Perspectives in Nutraceutical Research (2021) (0)
The Consumption of Fast Food Favors Weight Increase in Young Hellenic Navy Personnel: A 10-Year Follow-Up Study. (2020) (0)
Semaglutide reduces fat accumulation in the tongue of obese women with polycystic ovary syndrome: A randomized, placebo-controlled prospective study (2021) (0)
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis (2013) (0)
Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study (2012) (0)
Lipid pattern alterations in PCOS. (2009) (0)
Semaglutide in Obesity: Unmet Needs in Men (2023) (0)
A practical method to determinethe “atherogenic lipoprotein phenotype” (2008) (0)
HEAD-TO-HEAD COMPARISON OF STATINS VERSUS FIBRATES IN REDUCING PLASMA FIBRINOGEN CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS (2016) (0)
O49 Comparison of the effects of metformin and rosiglitazone in anovulatory women with polycystic ovary syndrome (PCOS) (2003) (0)
A novel beneficial effect of liraglutide: the reduction in subclinical atherosclerosis in patients with type-2 diabetes. (2012) (0)
Editorial: Managing the cardiovascular risk associated with the metabolic syndrome. (2014) (0)
Predictors of lipoprotein particle size and subclasses in patients with OSA (2013) (0)
Does Iodine Influence the Metabolism of Glucose? (2023) (0)
Abstract 18967: Analysis of Vitamin D Levels in Patients With and Without Statin-induced Myalgia - A Systematic Review and Meta-analysis of 7 Studies with 2416 Patients (2014) (0)
C-reactive protein and fibrinogen are strong predictors of the cardiovascular outcome in subjects with subclinical atherosclerosis and the metabolic syndrome (2011) (0)
THE ATHEROGENIC LIPOPROTEIN PHENOTYPE AS PREDICTOR OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON-CORONARY FORMS OF ATHEROSCLEROSIS (2008) (0)
Cardiovascular Preventive Management in Pre-Elderly and Elderly Patients with Type 2 Diabetes Mellitus in Primary Care (2016) (0)
Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL (2022) (0)
P251 EZETIMIBE WITH OR WITHOUT SIMVASTATIN INCREASES SMALL DENSE LOW-DENSITY LIPOPROTEINS IN HEALTHY MEN – A RANDOMIZED TRIAL (2010) (0)
Absolute Hyperglycemia versus Stress Hyperglycemia Ratio for the Prognosis of Hospitalized Patients with COVID-19 in the First Months of the Pandemic: A Retrospective Study (2022) (0)
Low circulating levels of HDL-cholesterol in women with PCOS and no other lipid abnormalities are associated to increased carotid intima media thickness and finding of atherogenic plaques. (2009) (0)
Small dense low-density lipoproteins and peripheral arterial disease (2009) (0)
When periods stop: cardiovascular consequences of PCOS. (2009) (0)
When periods stop: cardiovascular consequences of PCOS. (2009) (0)
LDL size, density and receptor affinity variation during an oral load in mild hyper-triglyceridemic and normal subjects (2003) (0)
Immune checkpoint inhibitors-induced diabetes mellitus: a growing clinical presentation requiring our attention (2022) (0)
Liraglutide improves carotid intima-media thickness in pre-elderly and elderly patients with type-2 diabetes: an 18-month prospective, real life study (2017) (0)
Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons (2022) (0)
Advances in pharmacological treatment of type 1 diabetes during pregnancy (2019) (0)
The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam? (2014) (0)
Lipoprotein subclasses and early kidney dysfunction in young type 1 diabetes mellitus patients. (2023) (0)
The Clinical Significance of Small, Dense Low-Density Lipoproteins (2006) (0)
The malnutrition in the elderly: a clinical approach. (2004) (0)
Postprandial metabolism: from research to clinical practice (2013) (0)
Abstract 13035: High Plasma Levels of Endothelin-1 are Predictive of Future Cerebro- and Cardio-Vascular Events: a 20-Year Prospective Study (2012) (0)
Author response for "Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice. The case of GLP‐1 receptor agonists" (2019) (0)
Recent insights on atherogenic dyslipidemia and cardiovascular risk. (2009) (0)
1.P.321 ApoE genotype distribution in a low-cholesterol mediteranean poulation of Southern Italy (1997) (0)
Potassium Iodide in nuclear accidents: give it timely, swiftly and judiciously. (2022) (0)
Non-alcoholic Fatty Liver Disease, Metabolic syndrome, and Type 2 diabetes mellitus: Where do we stand today? (2022) (0)
Asymptomatic carotid lesion as marker of future cerebrovascular and cardiovascular events in the follow-up: correlation with markers of inflammation and the infections from cytomegalovirus, chlamydia pneumoniae, helicobacter pylori (2002) (0)
The Role of Physicians’ Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus (2022) (0)
Do We Need Better Lipid Tools for Cardiovascular Risk Assessment? (2008) (0)
Cardiovascular and Cardioprotective Agents in 2021. (2021) (0)
Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)] (2011) (0)
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis (2023) (0)
Low-density-lipoprotein heterogeneity and the metabolic syndrome. (2007) (0)
Smoking and Small, Dense Low-Density Lipoproteins (2013) (0)
Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials (2023) (0)
Use of the drug eluting stents with rapamicin in patients with anatomical or clinical patterns favouring restenosis: results of a 6-months follow-up on the first 100 patients (2004) (0)
Accumulation of remnant-like particles in normolipidemic men with premature coronary artery disease (2003) (0)
Elevated levels of non-HDL-cholesterol are relatively uncommon in women with PCOS and generally reflect LDL-cholesterol levels. (2009) (0)
Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes (2022) (0)
Lipid Guidelines and Cardiovascular Prevention: Let's Manage The Risk Of Our Patients! (2023) (0)
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up (2013) (0)
Serological, immunomorphological and bioinformatics analyses suggest Hsp60 is involved in Hashimoto’s thyroiditis pathogenesis. (2013) (0)
A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study (2023) (0)
W01-P-012 Drug eluting stents's use in patients with anatomical or clinical patterns favouring restenosis: A 6-months follow-up study (2005) (0)
PREDICTIVE ROLE OF ASYMPTOMATIC CAROTID LESIONS FOR CARDIOVASCULAR AND CEREBROVASCULAR, FATAL AND NON FATAL, EVENTS IN A 5-YEARS FOLLOW-UP STUDY (2008) (0)
The effect of statins on the differentiation and function of central nervous system cells. (2023) (0)
Capacity of HDL to Efflux Cellular Cholesterol from Lipid-Loaded Macrophages Is Reduced in Patients with Familial Hypercholesterolemia (2023) (0)
The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review (2017) (0)
Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and the metabolic syndrome. (2009) (0)
An update on rickettsiosis (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Manfredi Rizzo?

Manfredi Rizzo is affiliated with the following schools:

Manfredi Rizzo's Academic­Influence.com Rankings

Manfredi Rizzo's Degrees

Similar Degrees You Can Earn

Why Is Manfredi Rizzo Influential?

Manfredi Rizzo's Published Works

Published Works

What Schools Are Affiliated With Manfredi Rizzo?

Manfredi Rizzo's AcademicInfluence.com Rankings